Weekly Digest - May 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - May 2024
15 May 2024: Merck to showcase innovative oncology treatments at 2024 ASCO annual meeting
- Merck will present new data on four approved oncology medicines and four pipeline candidates across more than 25 cancer types at the 2024 ASCO meeting. Highlights include:
- New Phase 3 data on sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed ADC, for previously treated locally recurrent or metastatic TNBC
- Notable updates on KEYTRUDA’s efficacy in various cancers, marking its 10th anniversary since initial U.S. approval, including:
- Longer-term follow-up results from the Phase 3 KEYNOTE-859 study
- Patient-reported outcomes (PROs) from the Phase 3 KEYNOTE-A39/EV-302 trial
- Health-related quality of life (HRQoL) data from the Phase 3 KEYNOTE-671 study.
